Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | The safety and efficacy of hyper-CVAD plus blinatumomab and inotuzumab ozogamicin in Ph- ALL

In this video, Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the safety and efficacy of hyper-CVAD (cyclophosphamide, vincristine, doxorubicin and dexamethasone) in combination with blinatumomab and inotuzumab ozogamicin in patients with Ph- acute lymphoblastic leukemia (ALL), highlighting the overall responses rates (ORR) and measurable residual disease (MRD) negative responses observed with this combination. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

N.J.S. reports receiving research grants from Takeda Oncology, Astellas Pharma Inc., Stemline Therapeutics, Inc, and Xencor and has received honoraria from Amgen, Jazz Pharmaceuticals, Astellas Pharmac, Inc., Novartis and Pfizer.